AR035863A1 - Ligandos receptores de melanocortina - Google Patents
Ligandos receptores de melanocortinaInfo
- Publication number
- AR035863A1 AR035863A1 ARP020101471A ARP020101471A AR035863A1 AR 035863 A1 AR035863 A1 AR 035863A1 AR P020101471 A ARP020101471 A AR P020101471A AR P020101471 A ARP020101471 A AR P020101471A AR 035863 A1 AR035863 A1 AR 035863A1
- Authority
- AR
- Argentina
- Prior art keywords
- unit
- rings
- group
- compound
- aromatic carbocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
Abstract
Se revelan ligandos receptores de MC-3/MC-4, compuesto que incluyendo todas las formas enantioméricas y diasteroisoméricas y las sales farmacéuticamente aceptables de éste, dicho compuesto tiene la fórmula (1) en donde A es un sistema de anillo conformacionalmente restringido que se selecciona del grupo que consiste de: a) anillos carbocíclicos no aromáticos; b) anillos carbocíclicos aromáticos; c) anillos heterocíclicos no aromáticos; d) anillos heterocíclicos aromáticos; en donde dichos anillos comprenden de 5 a 8 átomos; W es una unidad pendiente que tiene la fórmula (2), en donde R se selecciona del grupo que consiste de: a) anillos carbocíclicos no aromáticos; b) anillos carbocíclicos aromáticos; c) anillos heterocíclicos no aromáticos; d) anillos heterocíclicos aromáticos; los anillos antes mencionados comprenden de 3 a 12 átomos; J se selecciona del grupo que consiste de: ) -[c(R'')d]k-; en donde cada R'' independientemente es hidrógeno, alquilo C1-12 lineal o ramificado, -SUB, dos unidades R'' se pueden tomar junto con un átomo de oxígeno para formar una unidad de carbonilo, dos unidades R'' de cualquier unidad J o una unidad R'' y una unidad R' de una unidad T se pueden tomar juntas para formar un anillo fusionado carbocíclico o heterocíclico, anillo biciclo, o anillo espiroanulado que comprende de 3 a 7 átomos; el índice d tiene el valor de 1 o 2; el índice k tiene el valor de 1 o 2; ii) -N-; iii) -NR'-, en donde R' es hidrógeno, alquilo C1-6 lineal o ramificado, o una unidad SUB; iv) -O-; v) -S-; vi) -P(O)- o -P(O)2-; vii) y mezclas de éstos; L es una unidad enlazante; B comprende una unidad que se selecciona del grupo que consiste de: a) hidrógeno; b) anillos carbocíclicos aromáticos sustituidos o no sustituidos; c) anillos heterocíclicos aromáticos sustituidos o no sustituidos; y d) mezclas de éstos; Y es una unidad pendiente que comprende por lo menos un heteroátomo; Z es una unidad pendiente, que comprende un anillo carbocíclico aromático. Una composición farmacéutica que comprende A) una cantidad eficaz de dicho compuesto; B) el balance de portadores, excipientes, e ingredientes auxiliares. Uso de un compuesto para fabricar una composición farmacéutica de acuerdo con un método para tratar un trastorno que comprende administrar una cantidad eficaz de dicho compuesto a un sujeto animal que necesita tratarse que se selecciona del grupo que consiste de resistencia a la insulina, intolerancia a la glucosa, diabetes mellitus Tipo 2, enfermedad de la arteria coronaria, presión sanguínea elevada, hipertensión, dislipidemia, cáncer, irregularidades menstruales, hirsutismo, infertilidad, y otras como se describe en la memoria, en un sujeto o animal que requiere tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28661001P | 2001-04-25 | 2001-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035863A1 true AR035863A1 (es) | 2004-07-21 |
Family
ID=23099366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101471A AR035863A1 (es) | 2001-04-25 | 2002-04-24 | Ligandos receptores de melanocortina |
Country Status (22)
Country | Link |
---|---|
US (3) | US6911447B2 (es) |
EP (1) | EP1390361A4 (es) |
JP (1) | JP2005503342A (es) |
KR (2) | KR100662309B1 (es) |
CN (1) | CN1543461A (es) |
AR (1) | AR035863A1 (es) |
AU (1) | AU2002254744B2 (es) |
BR (1) | BR0209193A (es) |
CA (1) | CA2444599A1 (es) |
CZ (1) | CZ20032806A3 (es) |
HU (1) | HUP0500870A3 (es) |
IL (1) | IL157969A0 (es) |
MA (1) | MA27016A1 (es) |
MX (1) | MXPA03009791A (es) |
NO (1) | NO20034774L (es) |
NZ (1) | NZ528262A (es) |
PE (1) | PE20021087A1 (es) |
PL (1) | PL373503A1 (es) |
RU (1) | RU2277535C2 (es) |
SK (1) | SK13222003A3 (es) |
WO (1) | WO2002085925A2 (es) |
ZA (1) | ZA200307439B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
AU2002322466B2 (en) | 2001-07-11 | 2007-08-30 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
FR2870243B1 (fr) | 2004-05-11 | 2010-11-19 | Centre Nat Rech Scient | Conjugues tripeptidiques agonistes de la msh |
FR2870242B1 (fr) | 2004-05-11 | 2010-08-20 | Inst Europeen Biologie Cellulaire | Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie. |
FR2870244B1 (fr) | 2004-05-11 | 2011-01-07 | Centre Nat Rech Scient | Conjugues dipeptidiques antagonistes de l'alpha-msh |
MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
DE602005025924D1 (en) * | 2004-09-20 | 2011-02-24 | Xenon Pharmaceuticals Inc | Royl-coa-desaturase |
EP1804799B1 (en) * | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5043668B2 (ja) * | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
JP5149009B2 (ja) * | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
JP5080256B2 (ja) * | 2004-09-20 | 2012-11-21 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用 |
MX2007003327A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
JP4731495B2 (ja) * | 2004-12-13 | 2011-07-27 | ルネサスエレクトロニクス株式会社 | 半導体装置 |
MX2007015216A (es) * | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
WO2007115182A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
US7964181B2 (en) * | 2006-03-30 | 2011-06-21 | Palatin Technologies, Inc. | Amino acid surrogates for peptidic constructs |
US8114844B2 (en) | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
WO2007115175A2 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
BRPI0709405A2 (pt) * | 2006-03-30 | 2011-07-12 | Palatin Technologies Inc | composto lineares ou cìclicos |
WO2008017852A1 (en) * | 2006-08-11 | 2008-02-14 | Palatin Technologies, Inc. | Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES |
JP2012512172A (ja) * | 2008-12-15 | 2012-05-31 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピペリジン誘導体の立体選択的合成 |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
CN102093260B (zh) * | 2009-12-14 | 2014-03-05 | 太景生物科技股份有限公司 | 哌啶衍生物的立体有择合成 |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
EP3333165B1 (en) * | 2015-08-04 | 2019-09-18 | Astellas Pharma Inc. | Piperazine derivative |
CN108742570B (zh) * | 2018-06-20 | 2021-10-01 | 博动医学影像科技(上海)有限公司 | 基于冠脉优势类型获取血管压力差的装置 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534536B1 (en) * | 1994-03-16 | 2003-03-18 | Bristol-Myers Squibb Company | Alkylsulfonamido heterocyclic thrombin inhibitors |
US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
SK282166B6 (sk) | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
WO1996002530A1 (en) | 1994-07-20 | 1996-02-01 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
US5767118A (en) | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
DE69533991T2 (de) | 1995-05-29 | 2006-04-13 | Pfizer Inc. | Dipeptide, die die ausschüttung von wachstumshormonen stimulieren |
GB9612276D0 (en) * | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
WO1998010653A1 (en) | 1996-09-13 | 1998-03-19 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
US5877182A (en) * | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
US5965565A (en) * | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
AU3768799A (en) | 1998-04-28 | 1999-11-16 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
JP4142253B2 (ja) | 1998-05-11 | 2008-09-03 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出特性を有する化合物 |
EP1085869A4 (en) | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
JP2003505435A (ja) * | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体ゴニストとしての置換ピペリジン |
AU4929601A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
JP2001316378A (ja) * | 2000-04-28 | 2001-11-13 | Takeda Chem Ind Ltd | ベンズアミド誘導体およびその用途 |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
MXPA03000063A (es) | 2000-06-28 | 2003-09-25 | Pfizer Prod Inc | Ligandos para receptores de malanocortina. |
AU2001288285B2 (en) | 2000-08-23 | 2005-09-29 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
US7291619B2 (en) | 2001-01-23 | 2007-11-06 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002059095A1 (en) * | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
KR20030076716A (ko) | 2001-02-28 | 2003-09-26 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체 |
US7015235B2 (en) | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
CA2438272A1 (en) * | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
ITTO20040423A1 (it) * | 2004-06-23 | 2004-09-23 | Thermoplay Spa | Piastra di distribuzione per uno stampo per lo stampaggio ad iniezione di materiali plastici. |
-
2002
- 2002-04-12 US US10/121,874 patent/US6911447B2/en not_active Expired - Fee Related
- 2002-04-24 EP EP02723988A patent/EP1390361A4/en not_active Withdrawn
- 2002-04-24 WO PCT/US2002/013340 patent/WO2002085925A2/en active Application Filing
- 2002-04-24 IL IL15796902A patent/IL157969A0/xx unknown
- 2002-04-24 KR KR1020037013997A patent/KR100662309B1/ko not_active IP Right Cessation
- 2002-04-24 KR KR1020067006130A patent/KR20060029706A/ko not_active Application Discontinuation
- 2002-04-24 CA CA002444599A patent/CA2444599A1/en not_active Abandoned
- 2002-04-24 JP JP2002583451A patent/JP2005503342A/ja active Pending
- 2002-04-24 AU AU2002254744A patent/AU2002254744B2/en not_active Ceased
- 2002-04-24 RU RU2003134019/04A patent/RU2277535C2/ru not_active IP Right Cessation
- 2002-04-24 NZ NZ528262A patent/NZ528262A/en unknown
- 2002-04-24 CN CNA028089308A patent/CN1543461A/zh active Pending
- 2002-04-24 AR ARP020101471A patent/AR035863A1/es not_active Application Discontinuation
- 2002-04-24 MX MXPA03009791A patent/MXPA03009791A/es not_active Application Discontinuation
- 2002-04-24 SK SK1322-2003A patent/SK13222003A3/sk unknown
- 2002-04-24 CZ CZ20032806A patent/CZ20032806A3/cs unknown
- 2002-04-24 BR BR0209193-3A patent/BR0209193A/pt not_active IP Right Cessation
- 2002-04-24 PL PL02373503A patent/PL373503A1/xx not_active Application Discontinuation
- 2002-04-24 HU HU0500870A patent/HUP0500870A3/hu unknown
- 2002-04-25 PE PE2002000348A patent/PE20021087A1/es not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307439A patent/ZA200307439B/en unknown
- 2003-10-24 NO NO20034774A patent/NO20034774L/no not_active Application Discontinuation
- 2003-10-24 MA MA27372A patent/MA27016A1/fr unknown
-
2004
- 2004-05-28 US US10/856,983 patent/US7087759B2/en not_active Expired - Fee Related
-
2006
- 2006-01-09 US US11/328,330 patent/US20060106059A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20034774L (no) | 2003-12-29 |
BR0209193A (pt) | 2005-10-25 |
US6911447B2 (en) | 2005-06-28 |
RU2003134019A (ru) | 2005-06-10 |
EP1390361A4 (en) | 2005-10-05 |
US7087759B2 (en) | 2006-08-08 |
EP1390361A2 (en) | 2004-02-25 |
US20040224985A1 (en) | 2004-11-11 |
IL157969A0 (en) | 2004-03-28 |
KR20060029706A (ko) | 2006-04-06 |
JP2005503342A (ja) | 2005-02-03 |
AU2002254744B2 (en) | 2006-02-23 |
US20060106059A1 (en) | 2006-05-18 |
HUP0500870A2 (hu) | 2005-12-28 |
RU2277535C2 (ru) | 2006-06-10 |
US20030109556A1 (en) | 2003-06-12 |
NO20034774D0 (no) | 2003-10-24 |
KR100662309B1 (ko) | 2007-02-28 |
WO2002085925A2 (en) | 2002-10-31 |
CN1543461A (zh) | 2004-11-03 |
KR20040007509A (ko) | 2004-01-24 |
NZ528262A (en) | 2007-04-27 |
WO2002085925A3 (en) | 2003-12-11 |
ZA200307439B (en) | 2004-10-06 |
CA2444599A1 (en) | 2002-10-31 |
PL373503A1 (en) | 2005-09-05 |
MA27016A1 (fr) | 2004-12-20 |
HUP0500870A3 (en) | 2008-03-28 |
MXPA03009791A (es) | 2004-01-29 |
PE20021087A1 (es) | 2003-02-20 |
SK13222003A3 (sk) | 2004-04-06 |
CZ20032806A3 (cs) | 2004-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035863A1 (es) | Ligandos receptores de melanocortina | |
AR031248A1 (es) | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos | |
HUP0203965A2 (en) | Indazole compounds and pharmaceutical compositions containing them | |
AR031973A1 (es) | Agonistas de los receptores beta2-adrenergicos, una composicion farmaceutica, y uso de dichos agonistas para la manufactura de un medicamento | |
BRPI0517461A (pt) | compostos farmacêuticos | |
EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
ES2193391T3 (es) | Antagonistas muscarinicos. | |
GT200000002A (es) | Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase. | |
KR930702292A (ko) | 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체 | |
RU2006105652A (ru) | Трициклические ингибиторы парп | |
SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
KR900015729A (ko) | 흥분성 아미노산 길항제 | |
AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
RU2440346C2 (ru) | Способ и композиция для стимуляции нейрогенеза и ингибирования дегенерации нейронов | |
AR029190A1 (es) | Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco | |
ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
AR026974A1 (es) | N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
ES2177543T3 (es) | Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. | |
DK0780125T3 (da) | Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler | |
KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 | |
KR880007462A (ko) | 빈뇨치료용 프로피오페논 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |